Genetic variations in genes encoding RANK, RANKL, and OPG in rheumatoid arthritis: A case-control study

Journal of Rheumatology

Volumn 37, Issue 5, 2010, Pages 900-904

  Assmann, Gunter ^a   Koenig, Jochem ^b   Pfreundschuh, Michael ^a   Epplen, Joerg T ^c   Kekow, Joern ^d   Roemer, Klaus ^a   Wieczorek, Stefan ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Osteoprotegerin; Polymorphism; RANK; RANKL; Rheumatoid arthritis; Single nucleotide polymorphism

Indexed keywords

GENOMIC DNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CHROMOSOME 13; CHROMOSOME 18; CHROMOSOME 8; CONTROLLED STUDY; EXON; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ALLELES; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REGRESSION ANALYSIS;

EID: 77951853110     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.091110     Document Type: Article

References (19)

1. Pettit AR, Ji H, von Stechow D, Müller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-1699 (Pubitemid 33062512)
2. Wei S, Siegal GP. Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets. Pathol Res Pract 2008;204:695-706.
3. Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001;44:253-259 (Pubitemid 32207017)
4. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann NY Acad Sci 2008;1143:123-150
5. Geusens PP, Landewé RB, Garnero P, Chen D, Dunstan CR, Lems WF, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006;54:1772-1777 (Pubitemid 43877926)
6. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000;43:821-826
7. Crotti TN, Ahern MJ, Lange K, Weedon H, Coleman M, Roberts-Thomson PJ, et al. Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. J Rheumatol 2003;30:2319-2324 (Pubitemid 37413887)
8. Wu Y, Liu J, Feng X, Yang P, Xu X, Hsu HC, et al. Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis. Arthritis Rheum 2005;52:3257-3268 (Pubitemid 41447109)
9. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology 2008;47:1635-1640
10. Hase H, Kanno Y, Kojima H, Sakurai D, Kobata T. Coculture of osteoclast precursors with rheumatoid synovial fibroblasts induces osteoclastogenesis via transforming growth factor beta-mediated down-regulation of osteoprotegerin. Arthritis Rheum 2008;58:3356-3365
11. Tunyogi-Csapo M, Kis-Toth K, Radacs M, Farkas B, Jacobs JJ, Finnegan A, et al. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. Arthritis Rheum 2008;58:2397-2408
12. Haynes D, Crotti T, Weedon H, Slavotinek J, Au V, Coleman M, et al. Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. Arthritis Rheum 2008;59:911-920 (Pubitemid 351990986)
13. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002;46:1744-1753 (Pubitemid 34774505)
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
15. Furuya T, Hakoda M, Ichikawa N, Higami K, Nanke Y, Yago T, et al. Associations between HLA-DRB1, RANK, RANKL, OPG, and IL-17 genotypes and disease severity phenotypes in Japanese patients with early rheumatoid arthritis. Clin Rheumatol 2007;26:2137-2141 (Pubitemid 350120354)
16. Wu H, Khanna D, Park G, Gersuk V, Nepom GT, Wong WK, et al. Interaction between RANKL and HLA-DRB1 genotypes may contribute to younger age at onset of seropositive rheumatoid arthritis in an inception cohort. Arthritis Rheum 2004;50:3093-3103 (Pubitemid 39371984)
17. Hsu YH, Niu T, Terwedow HA, Xu X, Feng Y, Li Z, et al. Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Hum Genet 2006;118:568-577 (Pubitemid 41825129)
18. Etzel CJ, Chen WV, Shepard N, Jawaheer D, Cornelis F, Seldin MF, et al. For the North American Rheumatoid Arthritis Consortium. Genome-wide meta-analysis for rheumatoid arthritis. Hum Genet 2006;119:634-641
19. Criswell LA, Gregersen PK. Current understanding of the genetic aetiology of rheumatoid arthritis and likely future developments. Rheumatology 2005;44:9-13.